NASDAQ:VCYT Veracyte (VCYT) Stock Price, News & Analysis → The only AI company to buy (From Porter & Company) (Ad) Free VCYT Stock Alerts $20.75 -0.24 (-1.14%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$20.69▼$21.4050-Day Range$18.86▼$23.5552-Week Range$18.61▼$30.52Volume771,387 shsAverage Volume704,436 shsMarket Capitalization$1.59 billionP/E RatioN/ADividend YieldN/APrice Target$27.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Veracyte alerts: Email Address Veracyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside32.5% Upside$27.50 Price TargetShort InterestBearish5.86% of Shares Sold ShortDividend StrengthN/ASustainability-1.02Upright™ Environmental ScoreNews Sentiment0.82Based on 7 Articles This WeekInsider TradingSelling Shares$248,819 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.19) to $0.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.45 out of 5 starsMedical Sector293rd out of 924 stocksMedical Laboratories Industry10th out of 19 stocks 3.3 Analyst's Opinion Consensus RatingVeracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageVeracyte has only been the subject of 2 research reports in the past 90 days.Read more about Veracyte's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.86% of the outstanding shares of Veracyte have been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Veracyte has recently increased by 2.05%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVeracyte has received a 67.11% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Management consulting for the pharmaceutical industry", and "DNA sequencers" products. See details.Environmental SustainabilityThe Environmental Impact score for Veracyte is -1.02. Previous Next 2.7 News and Social Media Coverage News SentimentVeracyte has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Veracyte this week, compared to 3 articles on an average week.MarketBeat Follows4 people have added Veracyte to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $248,819.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Veracyte is held by insiders.Read more about Veracyte's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Veracyte are expected to grow in the coming year, from ($0.19) to $0.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is -22.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is -22.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Veracyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution About Veracyte Stock (NASDAQ:VCYT)Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.Read More VCYT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCYT Stock News HeadlinesMay 31 at 9:42 AM | insidertrades.comMuna Bhanji Sells 1,539 Shares of Veracyte, Inc. (NASDAQ:VCYT) StockJune 2 at 7:52 AM | americanbankingnews.comInsider Selling: Veracyte, Inc. (NASDAQ:VCYT) Director Sells $32,319.00 in StockMay 28, 2024 | finance.yahoo.comVeracyte (VCYT) Fell Due to a Lack of Rising ProfitabilityMay 25, 2024 | americanbankingnews.comAnalyzing BioNexus Gene Lab (NASDAQ:BGLC) & Veracyte (NASDAQ:VCYT)May 22, 2024 | businesswire.comVeracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and CancerMay 10, 2024 | markets.businessinsider.comVeracyte’s Robust Performance and Growth Potential Reinforce Buy RatingMay 10, 2024 | markets.businessinsider.comVeracyte’s Strong Q1 Performance and Upbeat Outlook Justify Buy RatingMay 9, 2024 | finance.yahoo.comIs Veracyte, Inc. (NASDAQ:VCYT) Trading At A 43% Discount?May 8, 2024 | markets.businessinsider.comMaintaining Buy on Veracyte: Strong Q1 Performance and Progress Toward ProfitabilityMay 8, 2024 | finance.yahoo.comVeracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comVeracyte Inc (VCYT) (Q1 2024) Earnings Call Transcript Highlights: Strong Start with Revenue ...May 7, 2024 | finance.yahoo.comVeracyte Inc (VCYT) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strong Test PerformanceMay 7, 2024 | seekingalpha.comVeracyte, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | businesswire.comVeracyte Announces First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comHere's what to expect from Veracyte's earningsMay 6, 2024 | businesswire.com14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease UnderstandingApril 26, 2024 | bizjournals.comDiagnostics pioneer Bonnie Anderson launches PinkDx to focus on women's healthApril 22, 2024 | businesswire.comVeracyte to Release First Quarter 2024 Financial Results on May 7, 2024April 22, 2024 | finance.yahoo.comNew Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceApril 22, 2024 | businesswire.comNew Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceApril 17, 2024 | finance.yahoo.comVeracyte, Inc. (VCYT)April 16, 2024 | businesswire.comVeracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024April 2, 2024 | finance.yahoo.comWhat Makes Veracyte (VCYT) a Lucrative Investment?March 16, 2024 | finance.yahoo.comVCYT Apr 2024 30.000 callFebruary 27, 2024 | businesswire.comVeracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN GuidelinesSee More Headlines Receive VCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/02/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:VCYT CUSIPN/A CIK1384101 Webwww.veracyte.com Phone(650) 243-6300Fax650-243-6301Employees815Year Founded2006Price Target and Rating Average Stock Price Target$27.50 High Stock Price Target$34.00 Low Stock Price Target$21.00 Potential Upside/Downside+32.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,400,000.00 Net Margins-18.16% Pretax Margin-18.76% Return on Equity-1.42% Return on Assets-1.33% Debt Debt-to-Equity RatioN/A Current Ratio5.00 Quick Ratio4.69 Sales & Book Value Annual Sales$361.05 million Price / Sales4.39 Cash Flow$0.09 per share Price / Cash Flow223.57 Book Value$14.63 per share Price / Book1.42Miscellaneous Outstanding Shares76,450,000Free Float75,454,000Market Cap$1.59 billion OptionableOptionable Beta1.65 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Marc A. Stapley (Age 54)CEO & Director Comp: $1.55MMs. Rebecca Chambers (Age 46)Executive VP & CFO Comp: $901.49kDr. Phillip G. Febbo M.D. (Age 58)Chief Scientific & Medical Officer Comp: $657.74kMs. Annie McGuire (Age 43)Executive VP, General Counsel & Chief People Officer Comp: $791.72kDr. John Leite Ph.D. (Age 52)Chief Commercial Officer for CLIA Business Comp: $1.53MMr. Jonathan Wygant (Age 53)VP & Chief Accounting Officer Mr. Steven FrenchSenior VP & Chief Information OfficerMs. Karen PossematoSenior Vice President of Corporate Marketing, Communications & Commercial OperationsMr. Robert Brainin (Age 53)Executive VP & Chief Business Officer Ms. Corinne DananSenior Vice PresidentMore ExecutivesKey CompetitorsGenetronNASDAQ:GTHRadNetNASDAQ:RDNTGuardant HealthNASDAQ:GHFortreaNASDAQ:FTRECareDxNASDAQ:CDNAView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckySold 2,314 shares on 5/28/2024Ownership: 0.047%Muna BhanjiSold 1,539 sharesTotal: $32,319.00 ($21.00/share)Burney Co.Bought 7,176 shares on 5/22/2024Ownership: 0.034%California State Teachers Retirement SystemSold 3,788 shares on 5/16/2024Ownership: 0.095%Virtus Investment Advisers Inc.Bought 5,851 shares on 5/16/2024Ownership: 0.065%View All Insider TransactionsView All Institutional Transactions VCYT Stock Analysis - Frequently Asked Questions Should I buy or sell Veracyte stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VCYT shares. View VCYT analyst ratings or view top-rated stocks. What is Veracyte's stock price target for 2024? 5 brokers have issued 12 month target prices for Veracyte's shares. Their VCYT share price targets range from $21.00 to $34.00. On average, they anticipate the company's share price to reach $27.50 in the next twelve months. This suggests a possible upside of 32.5% from the stock's current price. View analysts price targets for VCYT or view top-rated stocks among Wall Street analysts. How have VCYT shares performed in 2024? Veracyte's stock was trading at $27.51 at the beginning of 2024. Since then, VCYT shares have decreased by 24.6% and is now trading at $20.75. View the best growth stocks for 2024 here. When is Veracyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our VCYT earnings forecast. How were Veracyte's earnings last quarter? Veracyte, Inc. (NASDAQ:VCYT) released its earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.17. The biotechnology company earned $96.84 million during the quarter, compared to the consensus estimate of $93.35 million. Veracyte had a negative trailing twelve-month return on equity of 1.42% and a negative net margin of 18.16%. Veracyte's revenue was up 17.5% on a year-over-year basis. During the same period last year, the company posted ($0.11) EPS. What ETFs hold Veracyte's stock? ETFs with the largest weight of Veracyte (NASDAQ:VCYT) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM), Invesco Biotechnology & Genome ETF (PBE), Global X Telemedicine & Digital Health ETF (EDOC), ROBO Global Artificial Intelligence ETF (THNQ), ARK Innovation ETF (ARKK), WisdomTree BioRevolution Fund (WDNA) and ARK Next Generation Internation ETF (ARKW). What guidance has Veracyte issued on next quarter's earnings? Veracyte updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $402.0 million-$410.0 million, compared to the consensus revenue estimate of $397.8 million. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO). Who are Veracyte's major shareholders? Veracyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.66%), Sumitomo Mitsui Trust Holdings Inc. (4.46%), Nikko Asset Management Americas Inc. (4.38%), Champlain Investment Partners LLC (3.53%), Bamco Inc. NY (1.46%) and William Blair Investment Management LLC (0.97%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John L Bishop, Karin Eastham, Marc Stapley and Muna Bhanji. View institutional ownership trends. How do I buy shares of Veracyte? Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Veracyte have any subsidiaries? The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.Read More This page (NASDAQ:VCYT) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBill Gates is all about this tiny $2 stockTimothy SykesBill Clinton Backing Biden Replacement???The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.